Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Novartis Subsidiary Announces New Plant

Tuesday, June 30, 2020 04:58 PM EDT Updated: Wednesday, July 1, 2020 09:09 AM EDT
By Wes Mills

Advanced Accelerator Applications, a subsidiary of global healthcare giant Novartis AG, has announced plans to build a 50,000-square-foot manufacturing plant near Indianapolis International Airport, hiring as many as 50 people to staff the facility.

Financial details were not disclosed.

This will be the company’s second U.S. manufacturing site for currently approved therapy and pipeline drug candidates.

The Radioligand Therapy manufacturing plant will be located within the Purdue Research Park in Indianapolis. The site will produce targeted radioligand drugs used in the treatment of cancer.

“We believe that Radioligand Therapy has the potential to become a major pillar of cancer treatment. We are also proud to support the communities in which we operate by creating skilled jobs and promoting economic growth,” said Sidonie Golombowski-Daffner, chair and president, Advanced Accelerator Applications.

AAA said the facility will significantly expand the company’s manufacturing capacity in the U.S. and will feature state-of-the-art, advanced manufacturing technologies. The company says the treatment targets specific tumor cells and has less of an impact on surrounding healthy tissue.

The company expects operations to begin in 2023.

Story Continues Below

Most Popular Stories

Perspectives

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

In the hustle and bustle of our professional lives, we often find ourselves engrossed in the intricacies of our trades. However, amidst our daily routines, there exists a unique opportunity to broaden our horizons and delve into the critical issues facing the state of Indiana. ...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service